OpenEvidence Secures $200 Million Funding for AI Medical Platform
The healthcare AI startup, OpenEvidence, has raised $200 million in a new funding round. This places their valuation at $6 billion. The funding round was led by Google Ventures, with participation from Sequoia, Kleiner Perkins, Thrive Capital, Coatue, and others.
OpenEvidence is often described as “ChatGPT for doctors,” but it focuses on aggregating and, just as importantly, verifying medical research. In this way, it enables clinicians to access evidence-based guidance for patient care, and pretty quickly. The startup provides The New England Journal of Medicine and JAMA with reliable and up-to-date information, having signed content agreements with them as well. This is a big deal if you look at the recent exposure of researchers falsifying data.
The funding will be used to support global expansion, enhance AI capabilities, and accelerate the platform’s integration into hospitals and clinics all over the world.
Organising Medical Knowledge for Clinicians
Daniel Nadler and Zachary Ziegler founded OpenEvidence in 2021 to address the challenge of information overload in medicine. The picture is dismal:
Researchers publish thousands of new studies every day. Understaffed hospitals already overstretch clinicians. No doctor can keep up with that amount of literature.
OpenEvidence comes in here. Their retrieval-augmented generation (RAG) and structured medical ontologies like SNOMED CT and MeSH link every response to its source, ensuring that clinicians can verify findings. Users interact via natural-language questions, and the underlying engine filters and ranks the data for accuracy.
‘Doctors face too much information and too little time,’ said Nadler. ‘OpenEvidence gives them verified insights instantly.’
Backing from Leading Investors
The $200 million round drew major attention from top-tier investors: Google Ventures, Sequoia, and Kleiner Perkins led the round, alongside Thrive Capital and Coatue. The funding reflects confidence in OpenEvidence’s unique results in combining AI with clinical evidence.
Investors cited the platform’s precision, transparency, and adoption in hospitals as reasons for backing the company. OpenEvidence competes with AI solutions like Google’s Med-PaLM and Amazon HealthScribe but differentiates itself by training exclusively on peer-reviewed medical data.
What adoption?
Scaling Clinical AI Across Hospitals
OpenEvidence now manages over 15 million medical consultations per month, nearly doubling usage since July. The platform is used in over 10,000 hospitals and medical centres, with 40% of U.S. physicians logging in daily.
With the new funding, the company plans to expand into Europe and Asia, retraining models on local journals and languages. It is also developing multimodal capabilities, allowing the AI to analyse medical imaging alongside text.
The startup recently launched DeepConsult, an AI agent that autonomously conducts advanced medical research and frees up doctors to focus on patient care.
How OpenEvidence Bridges Research and Practice
OpenEvidence aims to close the gap between medical research and clinical practice. Organising and visualising evidence as they do make for faster, safer and informed decisions for the typically busy and overstressed clinician.
The startup’s team includes experts from Harvard, MIT, and UCLA, bringing their experience in AI, computer science, and medical research. The result has been a palpable increase in scientific rigour and practical usability for clinicians.
As Nadler explained, “Our mission is to organise and expand the world’s collective medical knowledge. Every doctor should have the right information at the right time.”
More News: NewLimit Raises $45 Million to Advance Longevity Research
A Growing Market for Clinical AI
The demand for AI-driven medical tools is increasing, driven by the sheer rapid growth of research, plus the need for better decision support in healthcare. OpenEvidence is at the forefront of industry trust in its evidence-based AI system.
The $200 million raise positions the company for rapid global expansion, scaling adoption in hospitals and integrating multimodal AI features. With a proven platform and strong investor backing, OpenEvidence is poised to transform how clinicians access and apply medical knowledge.
To stay updated on crypto venture capital funding and market trends, visit our venture capital news section for more insights.
